Redhill Biopharm Stock Price, News & Analysis

RedHill Biopharma has completed the last patient enrollment in Part A of its Phase 2/3 study evaluating RHB-107 (upamostat) for non-hospitalized patients with symptomatic COVID-19. This study is being conducted in the U.S. and South Africa, with top-line results expected in Q1 2022. RHB-107 is a novel antiviral designed to be effective against emerging viral variants. In parallel, data for another candidate, opaganib, has been submitted for regulatory reviews. RedHill focuses on gastrointestinal and infectious diseases, promoting treatments like Movantik and Talicia.

RedHill Biopharma (RDHL) has completed enrollment for Part A of its Phase 2/3 study of RHB-107 (upamostat), a once-daily oral treatment for symptomatic COVID-19 patients not requiring hospitalization. The study, conducted in the U.S. and South Africa, aims to evaluate safety, tolerability, and dose selection. Top-line results are expected in Q1 2022. RHB-107 targets human cell factors and aims to be effective against emerging variants. Concurrently, data packages for another COVID-19 drug, opaganib, have been submitted for regulatory review.

RedHill Biopharma Ltd. (Nasdaq: RDHL) announced that Chief Business Officer Guy Goldberg will present at two upcoming virtual conferences: the H.C. Wainwright 7th Annual Israel Conference on November 15, 2021, and the German Equity Forum from November 22-24, 2021. The presentations will cover the company's biopharmaceutical focus on gastrointestinal and infectious diseases, including ongoing clinical trials for various therapies. Webcasts of both presentations will be available for 30 days post-event. More details can be found on RedHill's investor relations page.

RedHill Biopharma Ltd. (Nasdaq: RDHL) has entered a strategic agreement with South Korea's Kukbo Co. Ltd. for a $10 million private placement, sold in two tranches. The first tranche of $5 million has been completed, issuing 827,586 American Depositary Shares (ADSs) at $6.04 each, a 20% premium. Kukbo will have a six-month option for licensing RedHill's late-stage clinical assets in select Asian territories. This investment aims to support the advancement of RedHill's COVID-19 therapeutic, opaganib, among others.

RedHill Biopharma (NASDAQ:RDHL) recently presented new analyses of Talicia^® and Movantik^® at the ACG 2021 Annual Scientific Meeting. The findings support Talicia's recommendation as a first-line therapy for H. pylori eradication due to low resistance rates. Talicia's studies indicate that unique dosing achieves high eradication rates. Movantik demonstrated rapid symptom relief for extreme opioid-induced constipation in pivotal trials, with a favorable safety profile. Both products address significant healthcare challenges, with Talicia highlighting the clinical detriments of clarithromycin use.

RedHill Biopharma (Nasdaq: RDHL) has presented new data analyses for Talicia and Movantik at the ACG 2021 Annual Scientific Meeting.

The Talicia analyses highlight the high utilization of clarithromycin despite resistance issues and suggest that Talicia's dosing leads to effective H. pylori eradication. The Movantik data demonstrate its efficacy in providing rapid relief from severe opioid-induced constipation.

These studies reinforce the competitive positioning of Talicia and Movantik in the market, addressing significant public health concerns.

RedHill Biopharma Ltd. (Nasdaq: RDHL) plans to present a corporate overview at the BIO-Europe Digital Conference from October 25-28, 2021. Mr. Adi Frish, Chief Corporate & Business Development Officer, will lead the presentation. It will be available on-demand for 30 days on the company’s website. RedHill focuses on gastrointestinal and infectious diseases, with key products including Movantik®, Talicia®, and Aemcolo®. The company is advancing several late-stage clinical programs for conditions such as COVID-19 and Crohn's disease.

RedHill Biopharma Ltd. (Nasdaq: RDHL) announced that its board of directors and senior management purchased approximately 180,000 American Depositary Shares (ADSs) in open-market transactions from mid-September to October 15, 2021. This significant insider buying highlights the confidence that executives have in the company’s future. RedHill focuses on treatments for gastrointestinal and infectious diseases, with leading products like Movantik and Talicia. The company is also advancing several clinical programs targeting serious health issues.

RedHill Biopharma announced the granting of U.S. Patent No. 11,135,172 covering Talicia, its medicine for treating H. pylori infections, valid through 2034. This patent is the fifth listed in the FDA Orange Book for Talicia, which aims to combat the increasing resistance of H. pylori to traditional therapies. Talicia is an all-in-one capsule containing a proton pump inhibitor and two antibiotics, showing an 84% eradication rate in pivotal studies. H. pylori affects approximately 35% of the U.S. population, presenting a significant health risk.